Arcadia Biosciences amends merger with Roosevelt: extends deadline, revises share formula

Arcadia Biosciences, Inc.

Termination date extended from May 15, 2025 to August 15, 2025.
Exchange shares fixed at 90% of post-closing outstanding (floor of 80%); prior cash adjustments removed.
Eliminated definitions for Cash Amount, Surplus Amount, Deficit Amount, and Trading Price.
Closing condition amended to require tax-free exchange under Section 351(a) of the Code.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.